Atossa Therapeutics, Inc.
ATOSAnalyst Consensus
Price Target Trend
Rating Trend
Recent Price Targets
Recent Rating Actions
| Firm | Action | Rating | Date |
|---|---|---|---|
| Ascendiant Capital | maintain | Buy | Oct 1, 2026 |
| Ascendiant Capital | maintain | Buy | Apr 10, 2026 |
| HC Wainwright & Co. | maintain | Buy | Mar 26, 2026 |
| Ascendiant Capital | maintain | Buy | Dec 8, 2025 |
| Ascendiant Capital | maintain | Buy | Sep 22, 2025 |
| Ascendiant Capital | maintain | Buy | Jun 6, 2025 |
| Ascendiant Capital | maintain | Buy | Apr 21, 2025 |
| HC Wainwright & Co. | maintain | Buy | Mar 26, 2025 |
| HC Wainwright & Co. | maintain | Buy | Mar 12, 2025 |
| HC Wainwright & Co. | maintain | Buy | Jan 30, 2025 |
| HC Wainwright & Co. | maintain | Buy | Dec 13, 2024 |
| HC Wainwright & Co. | maintain | Buy | Dec 12, 2024 |
| Ascendiant Capital | maintain | Buy | Dec 9, 2024 |
| HC Wainwright & Co. | maintain | Buy | Nov 13, 2024 |
| HC Wainwright & Co. | maintain | Buy | Nov 5, 2024 |
| HC Wainwright & Co. | maintain | Buy | Oct 31, 2024 |
| Ascendiant Capital | maintain | Buy | Sep 11, 2024 |
| HC Wainwright & Co. | maintain | Buy | Aug 12, 2024 |
| HC Wainwright & Co. | maintain | Buy | Jun 28, 2024 |
| Ascendiant Capital | maintain | Buy | Jun 6, 2024 |
| HC Wainwright & Co. | maintain | Buy | May 13, 2024 |
| HC Wainwright & Co. | maintain | Buy | Apr 16, 2024 |
| HC Wainwright & Co. | maintain | Buy | Apr 2, 2024 |
| Ascendiant Capital | maintain | Buy | Sep 17, 2020 |
| Maxim Group | upgrade | Hold →Buy | Dec 18, 2019 |
Earnings History
Next report: Nov 11, 2026 · EPS est. $-0.86| Report Date | EPS Actual | EPS Est. | Revenue Actual | Revenue Est. |
|---|---|---|---|---|
| Aug 7, 2026 | $-0.95 | $-1.02 | — | — |
| May 8, 2026 | $-1.11 | $-1.22 | — | — |
| Mar 25, 2026 | $-1.19 | $-1.14 | — | — |
| Nov 12, 2025 | $-1.05 | $-0.97 | — | — |
| Aug 12, 2025 | $-1.05 | $-0.90 | — | — |
| May 13, 2025 | $-0.75 | $-0.06 | — | — |
| Mar 25, 2025 | $-0.75 | $-0.90 | — | — |
| Nov 12, 2024 | $-0.75 | $-0.06 | — | — |
News
One CVR will attach to each outstanding share of Atossa common stock as of the close of business on October 19, 2026, and shares and CVRs will transfer together while stapled Shares issued after October 19, 2026 will also carry one attached CVR, subject to the terms of the CVR Agreement SEATTLE, Oct. 19, 2026 /PRNewswire/ -- Atossa Therapeutics, Inc. (Nasdaq: ATOS) ("Atossa" or the "Company"), a clinical-stage biopharmaceutical company developing innovative medicines in oncology and other areas …
Board declares one stapled CVR for each share of Atossa common stock outstanding as of October 19, 2026 record date or issued thereafter CVRs entitle holders to 25% of net proceeds from monetization of Atossa's first qualifying priority review voucher, subject to a $50 million aggregate payment cap SEATTLE, Oct. 9, 2026 /PRNewswire/ -- Atossa Therapeutics, Inc. (Nasdaq: ATOS) ("Atossa" or the "Company"), a clinical-stage biopharmaceutical company developing innovative medicines in oncology and o…
Shareholders would receive one CVR for each ATOS share held as of the record date or issued thereafter CVRs would entitle holders to 25% of net proceeds from monetization of Atossa's first qualifying priority review voucher, subject to a $50 million aggregate payment cap SEATTLE, Sept. 29, 2026 /PRNewswire/ -- Atossa Therapeutics, Inc. (Nasdaq: ATOS) ("Atossa" or the "Company"), a clinical-stage biopharmaceutical company developing innovative medicines in oncology and other areas of significant …
Panel at Harvard University will explore translating evidence in diseases of aging into new therapeutics and regulatory pathways SEATTLE, Sept. 24, 2026 /PRNewswire/ -- Atossa Therapeutics, Inc. (Nasdaq: ATOS) ("Atossa" or the "Company"), a clinical-stage biopharmaceutical company, today announced that Steven Quay, M.D.